Vasso Kostourou Research Group

- Dr Kostourou's Lab received a international competitive grant from Worldwide Cancer Research to investigate novel anti-angiogenic treatments for cancer. More

- Fighting cancer: FAK levels do matter. In a study published today at Nature Communication (DOI: 10.1038/ncomms3020), Fleming researcher Vassiliki Kostourou and colleagues demonstrated that Focal Adhesion Kinase (FAK) has a dose dependent effect in tumour growth and angiogenesis. This work emphasizes the importance of anti-angiogenic treatment in combating cancer and show that the effects of FAK inhibitors as anti-cancer agents are more complex than anticipated. The significance of this study is highlighted by the distribution of a press release from the NPG press office. It is has been also highlighted in web page. For more information please contact This email address is being protected from spambots. You need JavaScript enabled to view it.